Zhou Ting, Chen Zhiyuan, Humphries Brittany, Xie Feng
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Department of Health Research Methods, Evidence, and Impact, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4L8, Canada.
Qual Life Res. 2025 Mar;34(3):801-807. doi: 10.1007/s11136-024-03856-0. Epub 2024 Nov 27.
Health utility is a key input used to perform cost-utility analysis (CUA), which is increasingly used to inform resource allocation decisions.
To identify the sources and elicitation methods of health utilities used in CUAs in oncology.
We used the Tufts Cost-Effectiveness Analysis registry to identify oncology CUAs published in Medline between 1976 and 2021. Eligible CUAs had to include an oncology population (based on ICD-10 codes), report health utilities, and be published in English. The references of cited health utilities were traced to identify the original health utility study and the method of utility elicitation. Characteristic of included CUAs were summarized and the methods to derive health utilities were compared.
A total of 1512 CUAs in oncology were identified. The majority of CUAs (n = 1428, 94.4%) were model-based. Malignant neoplasm of breast and female genital organs was the most common population considered (n = 424, 28.0%). Among these CUAs, 8714 health utilities were identified. Upon review, the sources of 2096 (24.1%) health utilities could not be traced. Of the remaining 6618 health utilities, 1718 (26.0%) were obtained from original health utility study embedded in CUA in which expert opinion (n = 547, 31.8%) or EQ-5D (n = 479, 27.9%) was most frequently used. The 4900 health utilities (74.0%) that were cited from external studies were most often derived using the standard gamble (n = 1258, 25.7%) or EQ-5D (n = 1190, 24.3%).
Published health utilities are widely used in oncology CUAs, especially for model-based analyses. However, the identification, selection, and use of health utilities is suboptimal.
健康效用是用于进行成本效用分析（CUA）的关键输入，成本效用分析越来越多地用于为资源分配决策提供依据。
确定肿瘤学CUA中使用的健康效用的来源和获取方法。
我们使用塔夫茨成本效益分析登记处来识别1976年至2021年期间发表在Medline上的肿瘤学CUA。符合条件的CUA必须包括肿瘤学人群（基于ICD-10编码）、报告健康效用且以英文发表。追溯引用的健康效用的参考文献，以识别原始健康效用研究和效用获取方法。总结纳入的CUA的特征，并比较得出健康效用的方法。
共识别出1512篇肿瘤学CUA。大多数CUA（n = 1428，94.4%）基于模型。乳腺和女性生殖器官恶性肿瘤是最常考虑的人群（n = 424，28.0%）。在这些CUA中，识别出8714个健康效用。经审查，2096个（24.1%）健康效用的来源无法追溯。在其余6618个健康效用中，1718个（26.0%）来自CUA中嵌入的原始健康效用研究，其中最常使用专家意见（n = 547，31.8%）或EQ-5D（n = 479，27.9%）。从外部研究引用的4900个健康效用（74.0%）最常使用标准博弈法（n = 1258，25.7%）或EQ-5D（n = 1190，24.3%）得出。
已发表的健康效用在肿瘤学CUA中广泛使用，尤其是在基于模型的分析中。然而，健康效用的识别、选择和使用并不理想。
